



Press release from Emotra AB (publ)  
Göteborg, January 16, 2014

## Our new share issue begins today

Today, January 16, 2014, is the first day of the subscription period for Emotra's new rights issue. The general public is also invited to subscribe for shares in this issue and the subscription period is open until January 30, 2014. A fully subscribed issue will provide Emotra with an injection of approximately 9.7 MSEK, before issue costs. Emotra's memorandum, teaser and the subscription form can be found on Emotra's, AktieTorget's and Sedermera Fondkommission's web sites ([www.emotra.se](http://www.emotra.se), [www.aktietorget.se](http://www.aktietorget.se) and [www.sedermera.se](http://www.sedermera.se)). Emotra has received subscription commitments for a total of 4,188,180 SEK, which equals approximately 43% of the total issue value.

### This is Emotra

Suicide is the world's fourth most common cause of death. Every year, around 1 million people take their own lives. Every day, four Swedes commit suicide, while another 20–30 people try to. Emotra has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.

### Primary Objective of New Share Issue

The primary goal of Emotra AB's new issue is to finance the preparation and international launch of the company's method, EDOR. More precisely, this share issue is mainly intended to finance Emotra's investment in forging strong alliances with Europe's leading clinics. Emotra will collaborate with these clinics in carrying out multi-centre studies as well as several research projects that have the potential to radically change the way risk patients' suicide risks are diagnosed in the psychiatric realm.

### Summary of the Share Offering

---

Subscription period:	January 16–30, 2014.
Subscription price:	15.00 SEK.
Preferential right:	Each outstanding share entitles the owner to one (1) subscription right. Three (3) subscription rights allow the purchase of one (1) new share.
Record day:	January 10, 2014. The final day for trading in the company's shares with subscription rights was January 7, 2014 and the first day without subscription rights was January 8, 2014.
Number of shares in this issue:	The offering comprises 648,945 new shares.
Issue volume:	Approximately 9.7 MSEK.
Trading in subscription rights:	Trading in subscription rights will be carried out on AktieTorget during the period January 16–27, 2014.
Trading in PSS:	Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget from January 16, 2014 until the share issue has been registered at Bolagsverket. We expect this registration to be completed at the end of February 2014.
Number of shares outstanding before the new issue:	1,946,835 shares.
Value:	Appr. 29.2 MSEK (pre-money).
Regular lot size:	One (1) share.
Subscription commitments:	Emotra has received subscription commitments for a total of 4,188,180 SEK, which equals approximately 43% of the total issue value.

---

*Complete terms and instructions for this rights issue, as well as further information about subscriptions commitments, can be found in our published memorandum.*



#### **A word from Claes Holmberg, our CEO**

– We own a fantastic method, EDOR, which Lars-Håkan Thorell has developed over the course of many years. The purpose of this method is to detect depressed patients who are at risk of committing suicide. In order to secure market acceptance, fifteen internationally renowned clinics will be conducting their own clinical trials of EDOR. At present, we have signed collaborative agreements with three foreign research groups and are negotiating with further clinics that have expressed a clear interest in participating in these trials.

When the support for EDOR from these clinical teams has grown sufficiently strong, we will launch the method in Europe. We approach our work with a great deal of humility and our goal is to grow through our efforts with a sound and strong product. In order to secure market acceptance and thereafter launch EDOR in Europe, we are carrying out a rights issue in Emotra AB to which the general public is also invited to participate.

#### **Informational seminars and webinar**

In connection with our new share issue, Emotra will be holding informational seminars and a webinar in order to present the company's operations and future plans. These informational seminars are free of charge and we will be serving a light snack.

- Stockholm – January 20, 18.00 – Scandic Anglais (full).
- Stockholm – January 21, 18.00 – Scandic Anglais, Humlegårdsgatan 23.
- Göteborg – January 22, 18.00 – Hotell Radisson Blu, Södra Hamngatan 59-65.
- Malmö – January 23, 18.00 – Minc, Anckargripsgatan 3.
- Webinar at AktieTorget's web site – January 27, 10.00.

To register or for more information about our informational seminars, please contact:

Sedermera Fondkommission AB  
E-mail: [anmalan@sedermera.se](mailto:anmalan@sedermera.se)  
Telephone: +46 431 47 17 00

#### **Financial Advisor**

Emotra's Financial Advisor in connection with this new share issue is Sedermera Fondkommission.

#### **For further information about Emotra, please contact:**

Claes Holmberg, CEO  
Telephone: +46 708 25 45 47  
E-mail: [claes@emotra.se](mailto:claes@emotra.se)

Lars-Håkan Thorell, Head of Research  
Telephone: +46 733 95 31 20  
E-mail: [lars@emotra.se](mailto:lars@emotra.se)

#### **For further information about the new issue, please contact:**

Sedermera Fondkommission  
Telephone: +46 431 47 17 00  
E-mail: [nyemission@sedermera.se](mailto:nyemission@sedermera.se)

---

**Emotra AB** is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden  
Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)